A listing of dm-gastroenterology medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
The Revitalize-1 Study will look at a potential procedure called duodenal mucosal resurfacing (DMR). The DMR procedure acts on the first layer (mucosa) of the duodenum (the part of the small intestine located immediately after the stomach). By removing an excess layer, the treatment may improve blood sugar control. This …
To evaluate efficacy of barzolvolimab, compared to placebo, in reducing esophageal intraepithelial infiltration of mast cells as assessed by peak esophageal intraepithelial mast cell (PMC) count in EoE patients
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects with Severe Alcohol-Associated Hepatitis.
A two-part, randomized, placebo controlled, double blind, multicenter, Phase 3 study to evaluate the efficacy and safety of linerixibat for the treatment of cholestatic pruritus in participants with primary biliary cholangitis (PBC).
Multi-center study to demonstrate impact of IBD learning health system approach that enables patients and care teams to deliver optimal health and high value care
To evaluate the clinical response of multiple dose strengths of CIN-103 relative to placebo on abdominal pain and stool consistency (as a composite responder) in subjects with IBS-D (Irritable Bowel Syndrome Prominently Diarrhea) over 12 weeks of treatment and the safety and tolerability of multiple dose strengths of CIN-103 relative …
I am requesting a reliance agreement with the external IRB Advarra. The purpse is to treat a single patient with gastroparesis who has requested expanded access with tradipitant.By doing so, we will also monitor the efficacy of tradipitant in reducing individual symptoms associated with gastroparesis in this single patient and …
Approximately 50% of patients with celiac disease have continued symptoms despite at least 12 months of treatment with a gluten free diet. PRV-015, a mAb that blocks IL-15, has been shown to reduce intestinal inflammation and improve clinical symptoms induced by gluten consumption in a previous Phase 2a gluten-challenge study …